By Dr Heloisa Zaccaron Milioli

Journal articles

Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, 'JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer', Journal of Experimental and Clinical Cancer Research, 44, http://dx.doi.org/10.1186/s13046-025-03466-9

Chaffer CL; Milioli HH; San Juan BP; Dear RF; Liu JJ, 2025, 'Abstract 4744: State-gating cancer to prevent chemotherapy-resistance', Cancer Research, 85, pp. 4744 - 4744, http://dx.doi.org/10.1158/1538-7445.am2025-4744

Gemma C; Lai CF; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin LA; Lim E; Charles Coombes R; Pruneri G; Buluwela L; Ali S, 2024, 'Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer', Cancer Research, 84, pp. 4283 - 4297, http://dx.doi.org/10.1158/0008-5472.CAN-24-0013

Sahoo S; Ramu S; Nair MG; Pillai M; San Juan BP; Milioli HZ; Mandal S; Naidu CM; Mavatkar AD; Subramaniam H; Neogi AG; Chaffer CL; Prabhu JS; Somarelli JA; Jolly MK, 2024, 'Increased prevalence of hybrid epithelial/mesenchymal state and enhanced phenotypic heterogeneity in basal breast cancer', Iscience, 27, http://dx.doi.org/10.1016/j.isci.2024.110116

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7

McKinnon JC; Milioli HH; Purcell CA; Chaffer CL; Wadie B; Alexandrov T; Mitchell TW; Ellis SR, 2023, 'Enhancing metabolite coverage in MALDI-MSI using laser post-ionisation (MALDI-2)', Analytical Methods, 15, pp. 4311 - 4320, http://dx.doi.org/10.1039/d3ay01046e

Shehadeh-Tout F; Milioli HH; Roslan S; Jansson PJ; Dharmasivam M; Graham D; Anderson R; Wijesinghe T; Azad MG; Richardson DR; Kovacevic Z, 2023, 'Innovative thiosemicarbazones that induce multi-modal mechanisms to down-regulate estrogen-, progesterone-, androgen- and prolactin-receptors in breast cancer', Pharmacological Research, 193, pp. 106806, http://dx.doi.org/10.1016/j.phrs.2023.106806

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

Heng B; Bilgin AA; Lovejoy DB; Tan VX; Milioli HH; Gluch L; Bustamante S; Sabaretnam T; Moscato P; Lim CK; Guillemin GJ, 2020, 'Differential kynurenine pathway metabolism in highly metastatic aggressive breast cancer subtypes: beyond IDO1-induced immunosuppression', Breast Cancer Research, 22, http://dx.doi.org/10.1186/s13058-020-01351-1

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2

Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501

Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333

Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2017, 'Basal-like breast cancer: molecular profiles, clinical features and survival outcomes', BMC Medical Genomics, 10, http://dx.doi.org/10.1186/s12920-017-0250-9

Tishchenko I; Milioli HH; Riveros C; Moscato P, 2016, 'Extensive transcriptomic and genomic analysis provides new insights about luminal breast cancers', Plos One, 11, http://dx.doi.org/10.1371/journal.pone.0158259

Milioli HH, 2016, 'Life as an early career researcher: Interview with Heloisa Helena Milioli', Future Science Oa, 2, http://dx.doi.org/10.4155/fsoa-2016-0033

Oliveira NCS; Gomig THB; Milioli HH; Cordeiro F; Costa GG; Urban CA; Lima RS; Cavalli IJ; Ribeiro EMSF, 2016, 'Comparative proteomic analysis of ductal and lobular invasive breast carcinoma', Genetics and Molecular Research, 15, http://dx.doi.org/10.4238/gmr.15027701

Milioli HH; Vimieiro R; Tishchenko I; Riveros C; Berretta R; Moscato P, 2016, 'Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset', Biodata Mining, 9, http://dx.doi.org/10.1186/s13040-015-0078-9

Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P, 2015, 'The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set', Plos One, 10, http://dx.doi.org/10.1371/journal.pone.0129711

Milioli HH; Tishchenko I; Riveros C; Sakoff J; Berretta R; Moscato P, 2015, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', Annals of Oncology, 26, pp. iii31, http://dx.doi.org/10.1093/annonc/mdv121.08

Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2015, 'Molecular classification of basal-like breast cancer subtypes based on predictive survival markers', Annals of Oncology, 26, pp. iii15, http://dx.doi.org/10.1093/annonc/mdv117.11

Milioli HH; Sousa KS; Kaviski R; Oliveira NCDS; De Andrade Urban C; De Lima RS; Cavalli IJ; De Souza Fonseca Ribeiro EM, 2015, 'Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion', Cancer Genomics and Proteomics, 12, pp. 89 - 101

Conference Papers

Juan BPS; Hediyah-Zadeh S; Rangel L; Rodriguez V; Milioli HH; Kohane F; Purcell CA; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, 2022, 'The anti-androgen seviteronel sensitizes triple-negative breast cancer to chemotherapy', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), LA, New Orleans, 08 April 2022 - 13 April 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000892509505326&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Abstract PS18-17: Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/1538-7445.sabcs20-ps18-17

Lim E; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon EC; Portman N, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 110 - 110

Milioli HH, 2015, 'The IMPAKT of breast cancer research: Fundamental science and applied medicine', in Future Science Oa, http://dx.doi.org/10.4155/fso.15.69

Conference Presentations

Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA

Milioli HH; Tishchenko I; Riveros C; Berretta R; Moscato P, 2016, 'Basal-like breast cancers uncovered by genomic and transcriptomic profiles and patients' overall survival', presented at Sydney Cancer Conference, Sydney NSW, Australia

Milioli HH; Sanhueza C; Riveros C; Berretta R; Moscato P, 2016, 'Breast cancer molecular portraits of intrinsic subtypes and integrative clusters in the METABRIC data set', presented at 2nd World Congress on Controversies in Breast Cancer (CoBrCA), Barcelona, Spain

Milioli HH; Riveros C; Vimieiro R; Berretta R; Moscato P, 2016, 'Pairwise biomarker combinations and predictive modelling for breast cancer intrinsic subtypes', presented at 18th EMBL PhD Symposium, Heidelberg, Germany

Milioli HH; Vimieiro R; Tishchenko I; Riveros C; Berretta R; Moscato P, 2015, 'Refining the breast cancer molecular subtypes in the METABRIC data set', presented at World Congress on Controversies in Breast Cancer (CoBRA), Melbourne VIC, Australia

Conference Abstracts

Juan BPS; Hediyah-Zadeh S; Rangel L; Rodriguez V; Milioli HH; Kohane F; Purcell CA; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, 2022, 'Abstract 1029: The anti-androgen seviteronel sensitizes triple-negative breast cancer to chemotherapy', in Cancer Research, American Association for Cancer Research (AACR), Vol. 82, pp. 1029 - 1029, http://dx.doi.org/10.1158/1538-7445.am2022-1029

Heng B; Bilgin A; Tan V; Milioli H; Lovejoy D; Bustamante S; Gluch L; Moscato P; Lim C; Guillemin G, 2021, 'Aggressive breast cancer subtype eats tryptophan!', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 17, pp. 15 - 16, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000693805000020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2020, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034

Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Abstract P6-20-04: Activation of AR inhibits growth of endocrine-resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 79, pp. p6-20-04-p6-20-04, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-20-04

Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-21-05

Milioli HH; Sanhueza C; Berretta R; Moscato P, 2016, 'Breast Cancer Molecular Portraits of Intrinsic Subtypes and Integrative Clusters in the METABRIC Data Set', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12618

Milioli HH; Tishchencko I; Riveros C; Berretta R; Moscato P, 2015, 'Basal-like breast cancer subgroups uncovered by genomic and transcriptomic profiles and overall survival outcomes', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12444

Milioli HH; Tishchencko I; Riveros C; Sakoff J; Berretta R; Moscato P, 2015, 'Consensus on breast cancer cell lines classification for an effective and efficient clinical decision-making', in Annals of Oncology, Elsevier, presented at IMPAKT 2015 Breast Cancer Conference, http://dx.doi.org/10.1093/annonc/mdv121.08

Tishchencko I; Milioli HH; Riveros C; Moscato P, 2015, 'How intrinsic are luminal breast cancer subtypes?', in Asia Pacific Journal of Clinical Oncology, Wiley, presented at Hunter Cancer Research Alliance Annual Symposium, http://dx.doi.org/10.1111/ajco.12444

Milioli HH; Tishchencko I; Riveros C; Berretta R; Moscato P, 2015, 'Molecular classification of basal-like breast cancer subtypes based on predictive survival markers', in Annals of Oncology, Elsevier, presented at IMPAKT 2015 Breast Cancer Conference, http://dx.doi.org/10.1093/annonc/mdv117.11

Preprints

Alexandrou S; Lee CS; Fernandez KJ; Wiharja CE; Eshraghi L; Reeves J; Reed DA; Portman N; Phan Z; Milioli HH; Nikolic I; Cadell AL; Croucher DR; Simpson KJ; Lim E; Hickey TE; Millar EKA; Alves CL; Ditzel HJ; Caldon CE, 2025, JNK pathway suppression drives resistance to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, http://dx.doi.org/10.1101/2025.01.08.631992

Mckinnon J; Milioli H; Purcell C; Chaffer C; Wadie B; Alexandrov T; Mitchell T; Ellis S, 2023, Enhancing Metabolite Coverage in MALDI-MSI using Laser Post-Ionisation (MALDI-2)., http://dx.doi.org/10.26434/chemrxiv-2023-sptss

Back to profile page